An Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study

Overview of attention for article published in Trials, July 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)

Mentioned by

news: 1 news outlet

twitter: 4 X users

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 91 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 25 publications that cite this research output.

25

The most recent citing publications are shown below. View all 25 publications that cite this research output on Dimensions.

Safety, tolerability and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer’s Disease (ILiAD) trial

Preprint in medRxiv (May 2024)

Advances in synaptic PET imaging and intervention with synapse-targeted small-molecular drugs for dementia diagnosis and therapy

Article in Fundamental Research (April 2024)

Drug repurposing for neurodegenerative diseases

Book chapter (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.